Gabriele D'Uva

Prof. Gabriele D'Uva

University of Bologna, Bologna, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2015 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva
AAAlla Aharonov
Alla Aharonov
MLMattia Lauriola
Mattia Lauriola
DKDavid Kain
David Kain
YYYfat Yahalom-Ronen
Yfat Yahalom-Ronen
ETEldad Tzahor
Eldad Tzahor

9 May 2018 in Nature
Verified
Journal Article
Closed access
PDF file
GMGonzalo del Monte-Nieto
Gonzalo del Monte-Nieto
MRMirana Ramialison
Mirana Ramialison
AAArne A. S. Adam
Arne A. S. Adam
BWBingruo Wu
Bingruo Wu
AAAlla Aharonov
Alla Aharonov
RHRichard P. Harvey
Richard P. Harvey

16 September 2012 in Nature Immunology
Verified
Journal Article
Closed access
ALAya Ludin
Aya Ludin
TITomer Itkin
Tomer Itkin
SGShiri Gur-Cohen
Shiri Gur-Cohen
AMAlexander Mildner
Alexander Mildner
ESElias Shezen
Elias Shezen
TLTsvee Lapidot
Tsvee Lapidot

15 April 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
MMMarco Bruno Morelli
Marco Bruno Morelli
CBChiara Bongiovanni
Chiara Bongiovanni
SPSilvia Da Pra
Silvia Da Pra
CMCarmen Miano
Carmen Miano
FSFrancesca Sacchi
Francesca Sacchi
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva
Chemotherapy and targeted therapies have significantly improved the prognosis of oncology patients. However, these antineoplastic treatments may also induce adverse cardiovascular effects, which may lead to acute or delayed onset of cardiac dysfunction. These common cardiovascular complications, commonly referred to as cardiotoxicity, not only may require the modification, suspension, or withdrawal of life-saving antineoplastic therapies, with the risk of reducing their efficacy, but can also strongly impact the quality of life and overall survival, regardless of the oncological prognosis. The onset of cardiotoxicity may depend on the class, dose, route, and duration of administration of anticancer drugs, as well as on individual risk factors. Importantly, the cardiotoxic side effects may be reversible, if cardiac function is restored upon discontinuation of the therapy, or irreversible, characterized by injury and loss of cardiac muscle cells. Subclinical myocardial dysfunction induced by anticancer therapies may also subsequently evolve in symptomatic congestive heart failure. Hence, there is an urgent need for cardioprotective therapies to reduce the clinical and subclinical cardiotoxicity onset and progression and to limit the acute or chronic manifestation of cardiac damages. In this review, we summarize the knowledge regarding the cellular and molecular mechanisms contributing to the onset of cardiotoxicity associated with common classes of chemotherapy and targeted therapy drugs. Furthermore, we describe and discuss current and potential strategies to cope with the cardiotoxic side effects as well as cardioprotective preventive approaches that may be useful to flank anticancer therapies.

15 December 2010 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
GSGianluca Storci
Gianluca Storci
PSPasquale Sansone
Pasquale Sansone
SMSara Mari
Sara Mari
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva
STSimona Tavolari
Simona Tavolari
MBMASSIMILIANO BONAFE'
MASSIMILIANO BONAFE'

27 March 2011 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
ASAmir Schajnovitz
Amir Schajnovitz
TITomer Itkin
Tomer Itkin
Gabriele D'UvaGabriele D'Uva
Gabriele D'Uva
AKAlexander Kalinkovich
Alexander Kalinkovich
KGKarin Golan
Karin Golan
TLTsvee Lapidot
Tsvee Lapidot